| Autor: |
Tore K Kvien, Joseph Sexton, Espen A Haavardsholm, Sella A Provan, Jorgen Jahnsen, Silje Watterdal Syversen, Guro Løvik Goll, Ingrid Jyssum, Siri Mjaaland, Ludvig A Munthe, Gunnveig Grødeland, Kristin Kaasen Jørgensen, Hilde S Ørbo, Kristin H Bjørlykke, Anne T Tveter, Ingrid E Christensen, Grete B Kro, John T Vaage |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
RMD Open, Vol 10, Iss 2 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2056-5933 |
| DOI: |
10.1136/rmdopen-2023-003545 |
| Popis: |
Objectives To assess incidence, severity and predictors of COVID-19, including protective post-vaccination levels of antibodies to the receptor-binding domain of SARS-CoV-2 spike protein (anti-RBD), informing further vaccine strategies for patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive medication.Methods IMIDs on immunosuppressives and healthy controls (HC) receiving SARS-CoV-2 vaccines were included in this prospective observational study. COVID-19 and outcome were registered and anti-RBD antibodies measured 2–5 weeks post-immunisation.Results Between 15 February 2021 and 15 February 2023, 1729 IMIDs and 350 HC provided blood samples and self-reported COVID-19. The incidence of COVID-19 was 66% in patients and 67% in HC, with re-infection occurring in 12% of patients. Severe COVID-19 was recorded in 22 (2%) patients and no HC. No COVID-19-related deaths occurred. Vaccine-induced immunity gave higher risk of COVID-19 (HR 5.89 (95% CI 4.45 to 7.80)) than hybrid immunity. Post-immunisation anti-RBD levels |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
